10 Best Indian Stocks to Buy According to Billionaires

4. Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Number of Billionaires: 8

Billionaire Holdings: $279,239,959

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is a pharmaceutical company, with its products and services spread across active pharmaceutical ingredients (APIs), over-the-counter (OTC) medicines, biosimilars, generics, and branded generics. The company is actively involved in areas of cardiovascular, diabetology, dermatology, gastrointestinal, oncology, and pain management.

On March 26, Bio-Thera Solutions and Dr. Reddy’s Laboratories Limited (NYSE:RDY) reached commercialization and license agreements for BAT2506, a proposed Simponi Biosimilar, and BAT2206, a proposed Stelara Biosimilar. Under the agreement, Bio-Thera Solutions will be responsible for manufacturing and supply, while Dr. Reddy’s will seek regulatory approvals and work on commercialization in Southeast Asia.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) and Alvotech also recently announced that the FDA had accepted the biological license application submission for AVT03, a proposed biosimilar of Prolia and Xgeva. The acceptance marks an important milestone in bringing this medication to more patients in the US.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) reported impressive results for the third quarter of fiscal 2025, with consolidated revenues of $977 million, up 16% year-over-year and 4% sequentially. The gross profit margin increased 19 basis points from last year to approximately 59%. The profit after tax was $165 million, growing 2% compared to Q3 2024.

According to Insider Monkey’s database for Q4 2024, 8 billionaires held a stake in the company, with combined holdings of over $279 million, making it one of the best Indian stocks to buy.